Skip to content
Search

Latest Stories

Lord Swraj Paul: UK needs to invest in workforce

Countries across the globe, including India, are making efforts to ensure that their companies are equipped with skilled workers and Britain must follow suit to succeed after the Brexit, leading industrialist Lord Swraj Paul has said.

Paul, the founder of Caparo Group of industries, said the world was becoming more competitive and Britain must continue to invest in its workforce if it is to succeed.


He said governments everywhere were playing a key role in ensuring that companies are equipped with skilled workers.

"It is noteworthy that many developing countries such as India are also working very hard and successfully in this area," said Paul, who is also the Chancellor of the University of Wolverhampton.

He said the university had taken positive and progressive steps to help match need and demand of industries.

Britain voted by 52 per cent in favour of leaving the European Union in a referendum last year.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less